Spectinamides: A new class of semisynthetic antituberculosis agents that overcome native drug efflux

Nature Medicine

Volumn 20, Issue 2, 2014, Pages 152-158

  Lee, Richard E ^a   Hurdle, Julian G ^a,h,i   Liu, Jiuyu ^a   Bruhn, David F ^a   Matt, Tanja ^b   Scherman, Michael S ^c   Vaddady, Pavan K ^d,j   Zheng, Zhong ^a   Qi, Jianjun ^a   Akbergenov, Rashid ^b   Das, Sourav ^a   Madhura, Dora B ^d   Rathi, Chetan ^d   Trivedi, Ashit ^d   Villellas, Cristina ^e,h   Lee, Robin B ^a   Rakesh, ^a   Waidyarachchi, Samanthi L ^a   Sun, Dianqing ^a   McNeil, Michael R ^c   Ainsa, Jose A ^e,f   Boshoff, Helena I ^g   Gonzalez Juarrero, Mercedes ^c   Meibohm, Bernd ^d   Böttger, Erik C ^b   Lenaerts, Anne J ^c   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d UNIVERSITY OF TENNESSEE   (United States)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g National Institute for Allergy and Infectious Disease   (United States)

^h UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j JANSSEN RESEARCH FOUNDATION   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIDES; ANIMALS; ANTITUBERCULAR AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BACTERIAL PROTEINS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICE; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; RIBOSOMES; SPECTINOMYCIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84893661669     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3458     Document Type: Article

References (63)

1. Zumla, A., Raviglione, M., Hafner, R. & von Reyn, C.F. Tuberculosis. N. Engl. J. Med. 368, 745-755 (2013).
2. Global Tuberculosis Report, WHO 2012. (WHO, Geneva, Switzerland, 2012).
3. Silver, L.L. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71-109 (2011).
4. Newman, D.J. & Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311-335 (2012).
5. Carter, A.P. et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407, 340-348 (2000).
6. Borovinskaya, M.A., Shoji, S., Holton, J.M., Fredrick, K. & Cate, J.H. A steric block in translation caused by the antibiotic spectinomycin. ACS Chem. Biol. 2, 545-552 (2007).
7. Novak, E., Schlagel, C.A., LeZotte, L.A. & Pfeifer, R.T. The tolerance of high dose intravenous spectinomycin therapy in man. J. Clin. Pharmacol. 14, 442-447 (1974).
8. Akiyoshi, M., Yano, S. & Ikeda, T. [Ototoxicity of spectinomycin (author's transl)]. Jpn. J. Antibiot. 29, 771-782 (1976).
9. Thomas, R.C. & Fritzen, E.L. Spectinomycin modification. III. Spectinomycin analogs with C-3'-branched chain sugars. J. Antibiot. (Tokyo) 38, 208-219 (1985).
10. Woitun, E., Maier, R., Wetzel, B., Reuter, W. & Lechner, U. Modification of spectinomycin. Derivatives of 4-dihydro-4-deoxy-4(R)- aminospectinomycin. J. Antibiot. (Tokyo) 34, 22-27 (1981).
11. Maier, R., Woitun, E., Reuter, A., Reuter, W. & Wetzel, B. Modification of spectinomycin. Synthesis of 4-aminospectinomycins. J. Antibiot. (Tokyo) 34, 16-21 (1981).
12. Zurenko, G.E., Yagi, B.H., Vavra, J.J. & Wentworth, B.B. In vitro antibacterial activity of trospectomycin (U-63366F), a novel spectinomycin analog. Antimicrob. Agents Chemother. 32, 216-223 (1988).
13. Noskin, G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41 (suppl. 5), S303-S314 (2005).
14. Projan, S.J. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20, 219S-223S (2000).
15. Wiley, P.F., Argoudelis, A.D. & Hoesema, H. The chemistry of actinospectacin. IV. The determination of the structure of actinospectacin. J. Am. Chem. Soc. 85, 2652-2659 (1963).
16. Foley, L., Lin, J.T. & Weigele, M. Spectinomycin chemistry. II.) 9-Deoxy-4(R)-dihydrospectinomycin and 9-deoxyspectinomycin. J. Antibiot. (Tokyo) 31, 979-984 (1978).
17. Foley, L., Lin, J.T. & Weigele, M. Preparation of 7-deoxyspectinomycin and 7-deoxy-8-epi-4(R)-dihydrospectinomycin. J. Antibiot. (Tokyo) 32, 418-419 (1979).
18. Rosenbrook, W. Jr. & Carney, R.E. Spectinomycin modification. I 7-EPI-9-deoxy-4(R)-dihydrospectinomycin. J. Antibiot. (Tokyo) 28, 953-959 (1975).
19. Balganesh, M. et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob. Agents Chemother. 56, 2643-2651 (2012).
20. Friesner, R.A. et al. Glide: a new approach for rapid, accurate docking and scoring. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749 (2004).
21. Wilcken, R., Zimmermann, M.O., Lange, A., Joerger, A.C. & Boeckler, F.M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. Chem. 56, 1363-1388 (2013).
22. Galimand, M., Gerbaud, G. & Courvalin, P. Spectinomycin resistance in Neisseria spp. due to mutations in 16S rRNA. Antimicrob. Agents Chemother. 44, 1365-1366 (2000).
23. Zaunbrecher, M.A., Sikes, R.D. Jr., Metchock, B., Shinnick, T.M. & Posey, J.E. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 106, 20004-20009 (2009).
24. Honaker, R.W., Dhiman, R.K., Narayanasamy, P., Crick, D.C. & Voskuil, M.I. DosS responds to a reduced electron transport system to induce the Mycobacterium tuberculosis DosR regulon. J. Bacteriol. 192, 6447-6455 (2010).
25. Ramón-García, S. et al. Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG. Antimicrob. Agents Chemother. 56, 2074-2083 (2012).
26. Böttger, E.C., Springer, B., Prammananan, T., Kidan, Y. & Sander, P. Structural basis for selectivity and toxicity of ribosomal antibiotics. EMBO Rep. 2, 318-323 (2001).
27. Hobbie, S.N. et al. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc. Natl. Acad. Sci. USA 105, 20888-20893 (2008).
28. Hobbie, S.N. et al. Mitochondrial deafness alleles confer misreading of the genetic code. Proc. Natl. Acad. Sci. USA 105, 3244-3249 (2008).
29. Barnhill, A.E., Brewer, M.T. & Carlson, S.A. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob. Agents Chemother. 56, 4046-4051 (2012).
30. McKee, E.E., Ferguson, M., Bentley, A.T. & Marks, T.A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50, 2042-2049 (2006).
31. Hobbie, S.N. et al. Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria. Nucleic Acids Res. 35, 6086-6093 (2007).
32. Shcherbakov, D. et al. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol. Microbiol. 77, 830-840 (2010).
33. Drusano, G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2, 289-300 (2004).
34. Lenaerts, A.J., Gruppo, V., Brooks, J.V. & Orme, I.M. Rapid in vivo screening of experimental drugs for tuberculosis using .-interferon gene-disrupted mice. Antimicrob. Agents Chemother. 47, 783-785 (2003).
35. Lenaerts, A.J. et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49, 2294-2301 (2005).
36. Bissantz, C., Kuhn, B. & Stahl, M. A medicinal chemist's guide to molecular interactions. J. Med. Chem. 53, 5061-5084 (2010).
37. Kuhn, B., Mohr, P. & Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 53, 2601-2611 (2010).
38. Adams, K.N. et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145, 39-53 (2011).
39. Lee, R.E., Brennan, P.J. & Besra, G.S. Mycobacterium tuberculosis cell envelope. Curr. Top. Microbiol. Immunol. 215, 1-27 (1996).
40. Akbergenov, R. et al. Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin. Antimicrob. Agents Chemother. 55, 4712-4717 (2011).
41. Dartois, V. & Barry, C.E. III. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg. Med. Chem. Lett. 23, 4741-4750 (2013).
42. Louw, G.E. et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184, 269-276 (2011).
43. Siddiqi, N. et al. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 32, 109-111 (2004).
44. Madhura, D.B., Lee, R. & Meibohm, B. Pharmacokinetic profile of spectinomycin in rats. Pharmazie 68, 675-676 (2013).
45. Case, D.A. et al. AMBER 11. (University of California, San Francisco, 2010).
46. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard M7-A7 (Clinical Laboratory Standards Institute, Wayne, PA, 2006).
47. Hurdle, J.G. et al. A microbiological assessment of novel nitrofuranylamides as antituberculosis agents. J. Antimicrob. Chemother. 62, 1037-1045 (2008).
48. Mallari, J.P. et al. Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J. Med. Chem. 51, 545-552 (2008).
49. Springer, B., Lucke, K., Calligaris-Maibach, R., Ritter, C. & Bottger, E.C. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J. Clin. Microbiol. 47, 1773-1780 (2009).
50. Bruell, C.M. et al. Conservation of bacterial protein synthesis machinery: initiation and elongation in Mycobacterium smegmatis. Biochemistry 47, 8828-8839 (2008).
51. Pallotti, F. & Lenaz, G. Isolation and subfractionation of mitochondria from animal cells and tissue culture lines. Methods Cell Biol. 65, 1-35 (2001).
52. McKee, E.E., Grier, B.L., Thompson, G.S. & McCourt, J.D. Isolation and incubation conditions to study heart mitochondrial protein synthesis. Am. J. Physiol. 258, E492-E502 (1990).
53. Fernández-Silva, P., Acin-Perez, R., Fernandez-Vizarra, E., Perez-Martos, A. & Enriquez, J.A. In vivo and in organello analyses of mitochondrial translation. Methods Cell Biol. 80, 571-588 (2007).
54. Hornig-Do, H.T. et al. Nonsense mutations in the COX1 subunit impair the stability of respiratory chain complexes rather than their assembly. EMBO J. 31, 1293-1307 (2012).
55. Budha, N.R. et al. Pharmacokinetically-guided lead optimization of nitrofuranylamide antituberculosis agents. AAPS J. 10, 157-165 (2008).
56. Budha, N.R., Lee, R.B., Hurdle, J.G., Lee, R.E. & Meibohm, B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb.) 89, 378-385 (2009).
57. Lenaerts, A.J., Degroote, M.A. & Orme, I.M. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol. 16, 48-54 (2008).
58. De Groote, M.A. et al. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55, 1237-1247 (2011).
59. De Groote, M.A. et al. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 731-738 (2012).
60. Gonzalez-Juarrero, M., Woolhiser, L.K., Brooks, E., DeGroote, M.A. & Lenaerts, A.J. Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Antimicrob. Agents Chemother. 56, 3957-3959 (2012).
61. Ordway, D. et al. XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN- by CD4 T cells and participates in granuloma stability. J. Leukoc. Biol. 82, 1221-1229 (2007).
62. Rosas-Taraco, A.G. et al. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Biol. 41, 136-145 (2009).
63. Rosas-Taraco, A.G. et al. Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis (Edinb.) 91, 98-106 (2011).